Actinium Pharmaceuticals, Inc. (ATNM)
Stock Price:
$9.79 USD
-0.12 (-1.21%)
Updated Aug 14, 2020 3:37 PM EDT - Market open
Key Info
| Market Cap |
133.00M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-21.90M |
| Shares Out |
13.59M |
| EPS (ttm) |
-4.03 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$9.79 |
| Previous Close |
$9.91 |
| Change ($) |
-0.12 |
| Change (%) |
-1.21% |
| Day's Open |
10.02 |
| Day's Range |
9.66 - 10.14 |
| Day's Volume |
279,232 |
| 52-Week Range |
4.71 - 19.47 |
More Stats
| Market Cap |
133.00M |
| Enterprise Value |
127.92M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
13.59M |
| Float |
13.00M |
| EPS (basic) |
-3.9 |
| EPS (diluted) |
-4.03 |
| FCF / Share |
-3.79 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
451,384 |
| Short Ratio |
0.66 |
| Short % of Float |
3.43% |
| Beta |
1.80 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
42.96 |
| Revenue |
n/a |
| Operating Income |
-22.06M |
| Net Income |
-21.90M |
| Free Cash Flow |
-21.84M |
| Net Cash |
5.08M |
| Net Cash / Share |
0.37 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-133.84% |
| ROE |
-523.73% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$67.50*
(589.48% upside)
Low
45.0
Current: $9.79
High
90.0
Target: 67.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Operating Income | -22.07 | -23.83 | -26.91 | -26.85 | -24.83 | -22.48 | -6.59 | -7.95 | -3.28 |
| Net Income | -21.90 | -23.65 | -26.60 | -24.32 | -21.03 | -24.69 | -10.77 | -8.36 | -3.44 |
| Shares Outstanding | 4.98 | 3.53 | 2.22 | 1.62 | 1.27 | 0.91 | 0.76 | 0.04 | 0.03 |
| Earnings Per Share | -4.50 | -6.60 | -12.00 | -15.00 | -16.50 | -27.00 | -14.10 | -227.40 | -129.00 |
| Operating Cash Flow | -21.46 | -20.57 | -21.55 | -20.79 | -18.54 | -14.35 | -6.29 | -5.21 | -0.52 |
| Capital Expenditures | -0.06 | -0.10 | -0.02 | -0.06 | -0.05 | -0.15 | -0.02 | - | - |
| Free Cash Flow | -21.53 | -20.67 | -21.58 | -20.85 | -18.59 | -14.50 | -6.31 | -5.22 | -0.52 |
| Cash & Equivalents | 9.69 | 14.10 | 17.79 | 20.55 | 25.68 | 6.74 | 5.53 | 5.62 | 5.70 |
| Total Debt | 1.43 | 0.26 | - | - | 0.27 | 0.28 | 0.16 | 0.14 | 0.12 |
| Net Cash / Debt | 8.27 | 13.84 | 17.79 | 20.55 | 25.41 | 6.46 | 5.38 | 5.48 | 5.58 |
| Assets | 11.67 | 14.89 | 18.34 | 22.53 | 26.59 | 7.57 | 5.77 | 5.79 | 6.20 |
| Liabilities | 6.03 | 6.08 | 4.67 | 4.52 | 4.61 | 9.49 | 7.33 | 4.64 | 5.21 |
| Book Value | 5.64 | 8.81 | 13.67 | 18.01 | 21.97 | -1.92 | -1.56 | 1.15 | 0.99 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Actinium Pharmaceuticals, Inc. |
| Country |
United States |
| CEO |
Sandesh Seth |
Stock Information
| Ticker Symbol |
ATNM |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSEAMERICAN: ATNM |
Description
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies. Its lead product candidate is Iomab-B, which is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, for the treatment of patients with penta refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. The company was founded in 2000 and is based in New York, New York.